Qyuns Therapeutics Income Statement

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Operating Revenue	320.36	158.79	-	-	-
Other Revenue	-	-	-	9.66	21.35
Revenue	320.36	158.79	-	9.66	21.35
Revenue Growth (YoY)	613.19%	-	-	-54.74%	-
Cost of Revenue	88.31	66.6	-	-	-
Gross Profit	232.06	92.19	-	9.66	21.35
Selling, General & Admin	95.2	116.85	164.59	76.6	48.8
Research & Development	340.45	334.28	364.4	257.21	151.89
Other Operating Expenses	-15.25	-16.66	-14.74	-	-
Operating Expenses	420.39	434.47	514.26	333.82	200.69
Operating Income	-188.34	-342.28	-514.26	-324.16	-179.34
Interest Expense	-19.98	-23.39	-16.82	-18.69	-17.84
Interest & Investment Income	8.29	7.78	4.47	4.17	7.06
Currency Exchange Gain (Loss)	0.72	3.89	-0.43	14.46	-2.72
Other Non Operating Income (Expenses)	-1.85	-	-	-0.06	-240.18
EBT Excluding Unusual Items	-201.16	-354	-527.04	-324.28	-433.02
Gain (Loss) on Sale of Investments	3.61	4.24	5.7	11.9	6.48
Pretax Income	-197.55	-349.76	-521.33	-312.38	-426.54
Income Tax Expense	-0.07	-0.07	-0.07	-0.07	-0.07
Earnings From Continuing Operations	-197.48	-349.69	-521.26	-312.31	-426.47
Minority Interest in Earnings	5.69	14.11	13.51	14.12	15.43
Net Income	-191.79	-335.57	-507.75	-298.19	-411.04
Preferred Dividends & Other Adjustments	-	-	-	-	-112.77
Net Income to Common	-191.79	-335.57	-507.75	-298.19	-298.27
Shares Outstanding (Basic)	222	219	206	178	116
Shares Outstanding (Diluted)	222	219	206	178	116
Shares Change (YoY)	4.05%	6.70%	15.67%	52.95%	-
EPS (Basic)	-0.86	-1.53	-2.47	-1.68	-2.57
EPS (Diluted)	-0.86	-1.53	-2.47	-1.68	-2.57
Free Cash Flow	-214.61	-187.31	-308.56	-245.33	-180.55
Free Cash Flow Per Share	-0.97	-0.85	-1.50	-1.38	-1.55
Gross Margin	72.44%	58.06%	-	100.00%	100.00%
Operating Margin	-58.79%	-215.55%	-	-3354.95%	-840.05%
Profit Margin	-59.87%	-211.33%	-	-3086.22%	-1397.13%
Free Cash Flow Margin	-66.99%	-117.96%	-	-2539.08%	-845.71%
EBITDA	-157.88	-311.81	-484.13	-295.51	-155.65
EBITDA Margin	-49.28%	-196.36%	-	-	-
D&A For EBITDA	30.46	30.46	30.13	28.65	23.7
EBIT	-188.34	-342.28	-514.26	-324.16	-179.34
EBIT Margin	-58.79%	-215.55%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.